Clinical operational tolerance after renal transplantation: Current status and future challenges

Annals of Surgery

Volumn 252, Issue 6, 2010, Pages 915-928

  Orlando, Giuseppe ^a,b   Hematti, Peiman ^c   Stratta, Robert J ^b   Burke, George W ^d   Cocco, Pierpaolo Di ^e   Pisani, Francesco ^e   Soker, Shay ^b   Wood, Kathryn ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; BONE MARROW TRANSPLANTATION; CLINICAL OPERATIONAL TOLERANCE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FOLLOW UP; GOLD STANDARD; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPH NODE IRRADIATION; LYMPHOCYTE DEPLETION; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PREGNANCY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RHEUMATOID ARTHRITIS; SKIN GRAFT; SURVIVAL RATE; TREATMENT OUTCOME;

HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 78650179150     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181f3efb0     Document Type: Review

References (106)

1. Ashton-Chess J, Giral M, Soulillou JP, et al. Can immune monitoring help to minimize immunosuppression in kidney transplantation Transplant Int. 2009;22:110-119.
2. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation. 2003;76:1699-1704. (Pubitemid 38032417)
3. Sayegh MH, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet. 2007;369:1676-1678. (Pubitemid 46755378)
4. Ashton-Chess J, Giral M, Brouard S, et al. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation. 2007;84:1215-1219. (Pubitemid 351339307)
5. Orlando G, Soker S, Wood K. Clinical operational tolerance after liver transplantation. J Hepatol. 2009;50:1247-1257.
6. Lerut J, Bonaccorsi-Riani, E, Finet P, et al. Minimization of steroids in liver transplantation. Transplant Int. 2009;22:2-19.
7. Demetris AJ, Lunz JG III, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transplant Int. 2009;22:120-141.
8. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation. 2008;86:1370-1378.
9. Svendsen UG, Aggestrup S, Heilmann C, et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur Respir J. 1995;8:334-337.
10. Comerci GD, Williams TM, Kellie S. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J Heart Lung Transplant. 2009;28:743-745.
11. Merrill JP, Murray JE, Harrison JH. Successful homotransplantation of the human kidney between identical twins. JAMA. 1956;160:277-282.
12. Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transplant Immunol. 2004;13:117-130. (Pubitemid 39222026)
13. Weil R, Starzl TE, Porter KA, Kershaw M, Scrotter GPJ, Koep LJ. Renal iso-transplantation without immunosuppression. Ann Surg. 1980;192:108-110.
14. Zonnebelt SM, Belzer FO. Kidney transplantation in monozygotic twins discordant for Lupus. JAMA. 1981;245:68-69. (Pubitemid 11205578)
15. Burlingham WJ, Grailer AP, Fechner JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation. 1995;59:1147-1155.
16. Trivedi HL, Mishra VV, Vanikar AV, et al. Embryonic stem cell derived and adult hematopoietic stem cell transplantation for tolerance induction in a renal allograft recipient: a case report. Transplant Proc. 2006;38:3103-3108. (Pubitemid 44737971)
17. Burke GW, Ciancio G, Cirocco R, et al. Association of interleukin-10 with rejection-sparing effect in septic kidney transplant recipients. Transplantation. 1996;61:1114-1116. (Pubitemid 26120265)
18. Owens ML, Maxwell G, Goodnight J, et al. Discontinuance of immunosup-pression in renal transplant patients. Arch Surg. 1975;110:1450-1451.
19. Zoller KM, Cho SI, Cohen JJ, et al. Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int. 1980;18:110-114. (Pubitemid 10044821)
20. Najarian JS. Editorial comment. Arch Surg. 1975;110:1451.
21. Hussey JL. Letter: Discontinuance of immunosuppression. Arch Surg. 1975;111:614.
22. Uehling DT, Hussey JL, Weinstein AB, et al. Cessation of immunosuppression after renal transplantation. Surgery. 1976;79:278-282.
23. Van Buskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human al-lograft acceptance is associated with immune regulation. J Clin Invest. 2000;106:145-155. (Pubitemid 30437250)
24. low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol. 2007;178:3983-3995. (Pubitemid 46417669)
25. Fischer T, Schobel H, Barenbrock M. Specific immune tolerance during pregnancy after renal transplantation. Eur J Obst Gyn. 1996;70:217-219. (Pubitemid 27046629)
26. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol. 2005;7:241-246.
27. Dutta P, Burlingham WJ. Tolerance to noninherited maternal antigens in mice and humans. Curr Opin Organ Transplant. 2009;14:439-447.
28. Miller J, Mathew JM, Esquenazi V. Toward tolerance to human organ transplants: a few additional corollaries and questions. Transplantation. 2004;77:940-942. (Pubitemid 38436840)
29. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant. 2006;6:736-746. (Pubitemid 43345011)
30. Ballet C, Roussey-Kesler G, Aubin JT, et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant. 2006;6:2796-2801. (Pubitemid 44571703)
31. + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation. 2006;81:398-407. (Pubitemid 43255726)
32. + lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol. 2006;17:294-304.
33. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Is J Transplant. 2005;5:330-340. (Pubitemid 40179520)
34. Braudeau C, Ashton-Chess J, Giral M, et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation. 2008;86:130-136.
35. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA. 2007;104:15448-15453. (Pubitemid 47502937)
36. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem. 2008;103:1681-1692. (Pubitemid 351501902)
37. Sivozhelezov V, Braud C, Giacomelli L, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. J Cell Biochem. 2008;103:1693-1706. (Pubitemid 351501903)
38. Christensen LL, Grunnet N, Rüdiger N, et al. Indications of immunological tolerance in kidney transplantation. Tissue Antigens. 1998;51:637-644. (Pubitemid 28306468)
39. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510. (Pubitemid 36566340)
40. + T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant. 2008;8:338-347.
41. Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation. 2009;87:1092-1095.
42. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation- efficacy and safety at five years. Am J Transplant. 2005;5:1347-1353. (Pubitemid 40839424)
43. Calne R, Moffatt SD, Friend PJ, et al. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi. 2000;101:301-306.
44. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cy-closporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68:1613-1616.
45. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998;351:1701-1702. Erratum in: Lancet. 1998;352:408. (Pubitemid 28254534)
46. Agarwal A, Shen LY, Kirk AD. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transplant Immunol. 2008;20:6-11.
47. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76:120-129. (Pubitemid 36877125)
48. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation. 2005;80:1051-1059. (Pubitemid 41611927)
49. Ciancio G, Burke GW III. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant. 2008;8:15-20.
50. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic Am J Transplant. 2008;8:338-347.
51. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk Transplantation. 2005;79:1157-1159.
52. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memorylike phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005;5:465-474. (Pubitemid 40313337)
53. Trzonkowski P, Zilvetti M, Friend P, et al. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation. 2006;82:1342-1351. (Pubitemid 44834311)
54. Delis S, Ciancio G, Burke GW, et al. Donor bone marrow transplantation, chimerism and tolerance. Transplant Immunol. 2004;13:105-115. (Pubitemid 39222025)
55. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal al-lografts after bone marrow transplants from the same donors. Ann Int Med. 1991;114:954-955.
56. Helg C, Chapuis B, Bolle JF, et al. Renal transplantation without immuno-suppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation. 1994;58:1420-1422.
57. Jacobsen N, Taaning E, Ladefoged J, et al. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet. 1994;343:800. (Pubitemid 24098720)
58. Sorof JM, Koerper MA, Portale AA, et al. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation. 1995;59:1633-1635.
59. Butcher JA, Hariharan S, Adams MB, et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant. 1999;13:330-335. (Pubitemid 29392624)
60. Sellers MT, Deierhoi MH, Curtis JJ, et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation- 6-year follow-up. Transplantation. 2001;71:1681-1683. (Pubitemid 32574173)
61. Light J, Salomon DR, Diethelm AG, et al. Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls. Clin Transplant. 2002;16:317-324.
62. Chiang KY, Lazarus HM. Should we be performing more combined hematopoietic stem cell plus solid organ transplants Bone Marrow Transplant. 2003;31:633-642. (Pubitemid 36553472)
63. Billingham RE, Brent L, Medawar PB. Activity acquired tolerance of foreign cells. Nature. 1953;172:603-606.
64. Monaco AP, Clark AW, Wood ML, et al. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery. 1976;79:384-392.
65. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc. 1970;2:489-496.
66. Monaco AP, Wood ML, Maki T, et al. Attempt to induce unresponsiveness to human renal allografts with antilymphocyte globulin and donor-specific bone marrow. Transplant Proc. 1985;27:1312-1314. (Pubitemid 15128724)
67. Sykes M. Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation. 2009;87:309-316.
68. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation. 1991;51:70-75.
69. Mathew JM, Garcia-Morales RO, Carreno M, et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transplant Immunol. 2003;11:307-321. (Pubitemid 37120550)
70. Ciancio G, Burke GW, Moon J, et al. Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Med J. 2004;45:998-1003. (Pubitemid 40136655)
71. Trivedi HL, Vanikar AV, Vakil JM, et al. A strategy to achieve donor-specific hyporesponsiveness in cadaver renal allograft recipients by donor haematopoietic stem cell transplantation into the thymus and periphery. Nephrol Dial Transplant. 2004;19:2374-2377. (Pubitemid 39214136)
72. Trivedi HL, Shah VR, Vanikar AV, et al. High-dose peripheral blood stem cell infusion: a strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients. Pediatr Transplant. 2002;6:63-68. (Pubitemid 34269738)
73. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006;6:2121-2133. (Pubitemid 44199546)
74. Bühler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation. 2002;74:1405-1409.
75. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation. 1999;68:480-484. (Pubitemid 29416620)
76. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353-361. (Pubitemid 351159234)
77. Burlingham WJ, Jankowska-Gan E, VanBuskirk A, et al. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Hum Immunol. 2000;61:1395-1402. (Pubitemid 32102430)
78. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosup-pressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002;73:1386-1391. (Pubitemid 34547457)
79. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362-368. (Pubitemid 351159235)
80. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transplant Int. 2008;21:742-754.
81. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transplant Int. 2008;21:728-741.
82. Hematti P. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev. 2008;22:262-273.
83. Le Blanc K, Frassoni F, Ball L, et al. Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586. (Pubitemid 351626841)
84. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509-525. (Pubitemid 47620502)
85. Crop M, Baan C, Weimar W, et al. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transplant Int. 2009;22:365-376.
86. Ding Y, Xu D, Feng G, et al. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes. 2009;58:1797-806.
87. Dahlke MH, Hoogduijn M, Eggenhofer E, et al. MISOT Study Group. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation. 2009;88:614-619.
88. Strober S, Dhillon M, Schubert M, et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med. 1989;321:28-33. (Pubitemid 19170382)
89. Strober S, Benike C, Krishnaswamy S, et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation. 2000;69:1549-1554.
90. Strober S, Lowsky RJ, Shizuru JA, et al. Approaches to transplantation tolerance in humans. Transplantation. 2004;77:932-936. (Pubitemid 38436838)
91. Sawitzki B, Reinke P, Volk HD, et al. Autoimmunity and transplantation: a meeting at the crossroads in Berlin. Nat Immunol. 2008;9:447-449. (Pubitemid 351560507)
92. Lechler RI. Defining the "fingerprint" of clinical transplantation tolerance [abstract]. 8th International Conference on New Trends in Immunosuppression and Immunotherapy; 2008; Berlin.
93. Seyfert-Margolis S. New approaches to answer old questions [abstract]. 8th International Conference on New Trends in Immunosuppression and Im-munotherapy; 2008; Berlin.
94. Zarkhin V, Sarwal MM. Microarrays: monitoring for transplant tolerance and mechanistic insights. Clin Lab Med. 2008;28:385-410, vi.
95. Weintraub LA, Sarwal MM. Microarrays: a monitoring tool for transplant patients Transplant Int. 2006;19:775-788.
96. Newell KA, Larsen CP. Tolerance assays: measuring the unknown. Transplantation. 2006;81:1503-1509. (Pubitemid 43890885)
97. Najafian N, Albin MJ, Newell KA. How can we measure immunologic tolerance in humans J Am Soc Nephrol. 2006;17:2652-2663. (Pubitemid 44484655)
98. Kirk AD. Ethics in the quest for transplant tolerance. Transplantation. 2004;77:947-951. (Pubitemid 38436842)
99. Kirk AD. Clinical tolerance 2008. Transplantation. 2009;87:953-955.
100. Matthes-Martin S, Peters C, Königsrainer A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploiden-tical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood. 2000;96:3997-3999.
101. Mellgren K, Fasth A, Saalman R, et al. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol. 2005;84:755-757. (Pubitemid 41447811)
102. Donckier V, Troisi R, Toungouz M, et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transplant Immunol. 2004;13:139-146. (Pubitemid 39222028)
103. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transplantation. 2006;12:1523-1528. (Pubitemid 44594284)
104. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant. 2008;13:645-653.
105. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs. 2008;68:2113-2130
106. Dijke IE, Weimar W, Baan CC. Regulatory T cells after organ transplantation: where does their action take place Hum Immunol. 2008;69:389-398.